Skip to main content

Cambridge Bio to Distribute, Support Chan Adverse Event Test in Europe

NEW YORK (GenomeWeb News) — Cambridge BioScience today said it will distribute and support Chan Test’s potassium channel assays in Europe.
 
Cleveland-based Chan Test’s assay, based on ion channels, is designed to predict cardiac events associated with non-cardiac drugs.
 
Cambridge BioScience Managing Director Mike Kerns said his company expects “significant growth” for the assay due to “the rapidly growing interest in ion channels as primary targets in areas such as pain and epilepsy research.”
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.